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Antimicrobial susceptibility patterns of unusual nonfermentative 
gram-negative bacilli isolated from Latin America: report from the 
SENTRY Antimicrobial Surveillance Program (1997-2002)
Ana C Gales/+, Ronald N Jones*, Soraya S Andrade, Helio S Sader*
Disciplina de Doenças Infecciosas e Parasitárias, Departamento de Medicina, Universidade Federal de São Paulo,  
Rua Leandro Dupret 188, 04025-010 São Paulo, SP, Brasil *The Jones Group/JMI Laboratories, North Liberty, IA, US
The antimicrobial susceptibility of 176 unusual non-fermentative gram-negative bacilli (NF-GNB) collected from 
Latin America region through the SENTRY Program between 1997 and 2002 was evaluated by broth microdilution 
according to the National Committee for Clinical Laboratory Standards (NCCLS) recommendations. Nearly 74% of 
the NF-BGN belonged to the following genera/species: Burkholderia spp. (83), Achromobacter spp. (25), Ralstonia 
pickettii (16), Alcaligenes spp. (12), and Cryseobacterium spp. (12). Generally, trimethoprim/sulfamethoxazole (MIC50, 
≤ 0.5 µg/ml) was the most potent drug followed by levofloxacin (MIC50, 0.5 µg/ml), and gatifloxacin (MIC50, 1 µg/ml). 
The highest susceptibility rates were observed for levofloxacin (78.3%), gatifloxacin (75.6%), and meropenem (72.6%). 
Ceftazidime (MIC50, 4 µg/ml; 83.1% susceptible) was the most active β-lactam against B. cepacia. Against Achro-
mobacter spp. isolates, meropenem (MIC50, 0.25 µg/ml; 88% susceptible) was more active than imipenem (MIC50, 2 
µg/ml). Cefepime (MIC50, 2 µg/ml; 81.3% susceptible), and imipenem (MIC50, 2 µg/ml; 81.3% susceptible) were more 
active than ceftazidime (MIC50, >16 µg/ml; 18.8% susceptible) and meropenem (MIC50, 8 µg/ml; 50% susceptible) 
against Ralstonia pickettii. Since selection of the most appropriate antimicrobial agents for testing and reporting has 
not been established by the NCCLS for many of NF-GNB species, results from large multicenter studies may help to 
guide the best empiric therapy.
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Infections due to nonfermentative gram-negative 
bacilli (NF-GNB) other than Pseudomonas aeruginosa, 
Acinetobacter spp., and Stenotrophomonas maltophilia 
are uncommon but their incidence is increasing in the 
last years (Beringer & Appleman 2000, Gales et al. 2001, 
Saiman et al. 2001). NF-GNB are inhabitants of soil and 
water and can colonize and cause infections mainly in 
im-munocompromised hosts. NF-GNB have mainly been 
implicated as a cause of nosocomial outbreaks associated 
with infusion of contaminated fluids, use of foreign devices 
and contaminated tap water (Roberts et al. 1990, Hsueh et 
al. 1996, Labarca et al. 1999, Sader & Jones 2005). 
Identification of some of these unusual NF-GNB is dif-
ficult and automated systems may fail in identifying some 
species (Van Pelt et al. 1999). In addition, the taxonomy of 
many NF-GNB has frequently changed. Decisions about 
performing susceptibility testing are further complicated 
by the fact that no interpretative breakpoints have been 
established for most of the unusual NF-GNB (NCCLS 
2004). Furthermore, the results obtained with some organ-
isms by the disk diffusion method do not correlate with 
those obtained by conventional MIC methods (Fraser & 
This study was presented in part at 43rd Interscience Conference 
on Antimicrobial Agents and Chemotherapy, Chicago, Illinois. 
September 14-17, 2003.
+Corresponding author. E-mail: galesac@aol.com
Received 30 March 2005
Accepted 26 August 2005
Jorgensen 1997, NCCLS 2004). Thus, clinical microbiol-
ogy laboratories could face problems in identifying and 
susceptibility testing these pathogens.
We report the antimicrobial susceptibility profile of 
unusual NF-GNB isolated from the Latin American medi-
cal centers that participate in the SENTRY Antimicrobial 
Surveillance Program.
 
MATERIALs  AND  METHODs
Bacterial strains - A total of 176 unusual NF-GNB 
were collected from the Latin American region through the 
SENTRY Program between January 1997 and December 
2002. The distribution of species is shown in Table I. The 
NF-GNB were isolated from blood (118), respiratory tract 
(44), wound (10), and urine (4). All strains were isolated 
from hospitalized patients and only a single isolate per 
patient was evaluated. The isolates were identified to the 
species level by the participant medical center using con-
ventional biochemical tests and sent to the coordinating 
laboratory for identification confirmation and reference 
susceptibility testing. The identification confirmation 
was performed using the Vitek System (Hazelwood, MI) 
when  necessary.
Medical centers - The participant medical centers were 
distributed throughout twelve cities in seven countries: 
Brasília (2001-2002), Florianópolis (1997-2002), Rio de 
Janeiro (1997-1998), São Paulo (1997-2002), and Porto 
Alegre (1999-2002) in Brazil; Buenos Aires (1997-2002) 
and San Isidro (1997-2002) in Argentina; Santiago in Chile 
(2 sites, 1997-2000); Medellin in Colombia (1997-2000); 
Mexico City in Mexico (3 sites, 1997-2002); Montevideo, 
Uruguay (1997); and Caracas in Venezuela (1998-2002).
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Susceptibility testing - Antimicrobial susceptibility 
testing was performed using the reference broth mi-crodi-
lution method as described by the National Committee 
for Clinical Laboratory Standards (NCCLS 2003). The 
susceptibility and resistance rates were calculated accord-
ing to the NCCLS breakpoints (M100-S14) established for 
testing non-Enterobacteriaceae isolates (NCCLS 2004). 
Antimicrobial agents were obtained from the respective 
manufacturers. Quality control was performed by testing 
Pseudomonas aeruginosa ATCC 27853, Escherichia coli 
ATCC 25922, Staphylococcus aureus ATCC 29213, and 
Enterococcus faecalis ATCC 29212. 
REsULTs AND DIsCUssION
NF-GNB other than P. aeruginosa, Acinetobacter 
spp., and Stenotrophomonas maltophilia are uncommon 
pathogens; however, they represent a real challenge for the 
routine clinical microbiology laboratories since species 
identification is complex and antimicrobial susceptibility 
profile is unpredictable. Table I shows the frequency of 
occurrence of NF-GNB isolated from Latin American 
medical centers during the first six years of SENTRY 
program (1997-2002). B. cepacia (45.5%) was the most 
frequently isolated NF-GNB, independent of the year 
of isolation, followed by Achromobacter xylosoxidans 
(12.5%) and Ralstonia pickettii (9.1%). Overall the Brazil-
ian medical centers contributed with the largest number of 
strains (91 isolates; 51.7%) followed by the Argentinean 
(32 isolates; 18.1%) and Colombian (20 isolates, 11.4%) 
medical centers. A single Brazilian medical center (number 
048) provided 25% of the NF-GNB strains. 
The distribution of the NF-GNB according to the site 
of infection is demonstrated in Table II. The majority 
(67%) of NF-GNB strains were isolated from blood-
stream infections. All pathogens were more frequently 
isolated from bloodstream infections with the exception 
of Cryseobacterium spp. and Alcaligenes spp. isolates. 
Cryseobacterium spp. strains were equally isolated from 
blood and respiratory tract infections, while Alcaligenes 
spp. strains were more frequently isolated from skin and 
soft tissue infections. 
Antimicrobial susceptibility data on unusual NF-
GNB is very scarce (Gales et al. 2001, Jones et al. 2003, 
Sader & Jones 2005). Changes in the nomenclature, use 
of disk-diffusion technique, and the isolation of low 
number of isolates make difficult to consider most of the 
published data. The most recent NCCLS documents do not 
include recommendations for the optimal antimicrobial 
susceptibility testing method for these NF-GNB, nor the 
antimicrobial agents that should be tested (NCCLS 2003, 
2004). We tested a panel of antimicrobial agents with ac-
tivity against gram-negative bacilli by broth microdilution 
and used susceptibility breakpoints established for non-
Enterobacteriaceae to evaluate the antimicrobial suscepti-
bility profile of uncommon NF-GNB isolated from Latin 
American centers through the SENTRY Program. 
TABLE I
Frequency of occurrence of nonfermentative gram-negative 
bacilli isolated from Latin American medical centers  
(SENTRY Program, 1997-2002)
Organism  n (%)
Achromobacter spp.a   25 (14.2)
Alcaligenes spp.b  12 (6.8)
Burkholderia spp.c    83 (47.2)
Chryseobacterium spp.d 12 (6.8)
Comamonas acidovorans    4 (2.3)
Ralstonia pickettii  16 (9.1)
Ochrobactrum antropi  8 (4.5)
Pseudomonas oryzihabitans  7 (4.0)
Others e  9 (5.1)
Total  176 (100.0)
a: includes Achromobacter xylosoxidans (22) and Achromobacter 
spp. (3); b: includes Alcaligenes faecalis (6) and Alcaligenes spp. 
(6); c: includes Burkholderia cepacia (80) and Burkholderia 
gladioli (3); d: includes Chryseobacterium indologenes (6) 
and Chryseobacterium meningosepticum (6); e: includes Em-
pedobacter brevi (2), Myroides odoratum (1), Ralstonia spp. (1), 
Sphingomonas paucimobilis (2), Sphingobacterium spp. (1), and 
other NF-GNB (2).
TABLE II
Distribution of the nonfermentative gram-negative bacilli according to the site of infection  
(SENTRY Program, Latin America 1997-2002)
Organism (N) Blood N (%) Respiratory tract N (%) SST a  N (%) Urine N (%)
Achromobacter spp.b (25)   16 (64.0)   8 (32.0)   1 (4.0) -
Alcaligenes spp.c (12)     3 (25.0)   3 (25.0)     5 (41.7) 1 (8.3)
Burkholderia spp.d (83)   52 (62.7) 25 (30.1)   3 (3.6) 3 (3.6)
Chryseobacterium spp.e (12)    6 (50.0)   6 (50.0)   0 (0.0) 0 (0.0)
Ralstonia pickettii (16)    16 (100.0) 0 (0.0)   0 (0.0) 0 (0.0)
Others f (28)   25 (89.3) 2 (7.1)   1 (3.6) 0 (0.0)
Total 118 (67.0) 44 (25.0) 10 (5.7) 4 (2.3)
a: skin and soft tissue; b: includes Achromobacter xylosoxidans (22) and Achromobacter spp. (3); c: includes Alcaligenes faecalis 
(6) and Alcaligenes spp. (6); d: includes Burkholderia cepacia (80) and Burkholderia gladioli (3); e: includes Chryseobacterium 
indologenes (6); and Chryseobacterium meningosepticum (6); f: includes Comamonas acidovorans (4), Empedobacter brevi (2), 
Pseudomonas oryzihabitans (7), Myroides odoratum (1), Ralstonia spp. (1), Sphingomonas paucimobilis (2), Sphingobacterium 
spp. (1), and other NF-GNB (10).
573Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 100(6), October 2005
The in vitro activity of selected antimicrobial agents 
tested against the unusual NF-GNB isolated from the Latin 
American region is displayed in Table III. In general, the 
highest susceptibility rate was obtained with levofloxacin 
(78.3% susceptible) followed by gatifloxacin (75.6%) > 
meropenem (72.6%) > imipenem (69.9%) > trimethoprim/ 
sulfamethoxazole (68.6%), and piperacillin/tazobactam 
(67.4%). Although the fluoroquinolones had shown an 
identical in vitro potency (MIC50, 1 mg/ml), ciprofloxacin 
showed the lowest susceptibility rate (61.4%). The ami-
noglycosides, amikacin and gentamicin, demonstrated 
poor in vitro activity against NF-GNB inhibiting less than 
30% of isolates at the susceptible breakpoints.
The antimicrobial activity of selected antimicrobial 
agents against the main genus of NF-GNB is shown in 
Table IV. With the exception of imipenem and meropenem 
that inhibited 100% of the Alcaligenes spp. isolates, none 
of the antimicrobial agents tested inhibited 100% of other 
NF-GNB genus. 
Within the Burkholderia genus, B. cepacia complex 
represents the most important constituent as observed in 
this study. B. cepacia complex was subdivided by DNA-
DNA hybridization, whole-cell protein pattern similarity, 
and phenotypic markers into five genomic species or 
genomovars, including B. multivorans (formerly geno-
movar II), B. stabilis (formerly genomovar IV), and B. 
vietnamiensis (formerly genomovar V). Genomovar III 
can be further subdivided into two groups on the basis 
of recA sequences (groups IIIA and IIIB). More recently, 
four new members of the B. cepacia complex have been 
identified: genomovar VI, B. ambifaria (genomovar VII), 
B. pyrrocinia (genomovar IX), and B. anthina (genomo-
var VIII) (Detsika et al. 2003). The distinction of these 
genomic species is very difficult to achieve using only 
phenotypic tests. Thus, routine clinical microbiology 
laboratories will group these genomovars under a unique 
species named B. cepacia. B. cepacia complex isolates 
are intrinsically resistant to aminoglycosides and are 
often multidrug resistant (Beringer et al. 2000). Among 
Burkholderia spp. isolates, an important variation on the 
susceptibility rates of compounds belonging to the same 
class was noticed. Susceptibility rates varied from 79.5% 
for meropenem to 60.2% for imipenem, and from 83.1% 
for ceftazidime to 51.8% for cefepime. In this study, ceftaz-
idime (MIC50, 4 µg/ml; 83.1% susceptible) was the most 
active β-lactam against B. cepacia, in contrast to results 
reported by previous studies that showed meropenem as 
the most active β-lactam (Visalli et al. 1997, Bonacorsi 
et al. 1999). In addition, these studies also reported that 
trimethoprim/sulfamethoxazole was the most active non-
β-lactam drug. In the present study, levofloxacin (MIC50, 
1 µg/ml; 81.9% susceptible and gatifloxacin (MIC50, 1 µg/
ml; 79.5% susceptible) were more active than trimethop-
rim/sulfamethoxazole (MIC50, ≤ 0.5 µg/ml; 71.1% sus-
ceptible) against B. cepacia. These fluoroquinolones have 
shown good activity against Burkholderia spp. in previous 
studies (Biedenbach et al. 1999, Dawis et al. 2003). 
Achromobacter xylosoxidans was briefly classified 
as genus Alcaligenes but was recently reclassified as 
Achromobacter (Yabuuchi et al. 1998). A. xylosoxidans 
infections have been reported in patients with HIV infec-
tion, cancer, cystic fibrosis, transplant, as well as in neo-
nates (Hearn & Gander 1991, Dupon et al.1993, Dunne 
& Maisch 1995, Manfredi et al. 1997, Hernandez et al. 
1998). Reported case-fatality rates have varied from 3% 
for primary or catheter-associated bacteremia to 80% for 
neonatal infection (Duggan et al. 1996). Achromobacter 
strains are frequently resistant to aminoglycosides, am-
picillin, first- and second-generation cephalosporins, 
and chloramphenicol, but are usually susceptible to anti-
Pseudomonas third-generation cephalosporins, imipenem, 
and trimethoprim-sulfamethoxazole (Reverdy et al. 1984, 
Klinger & Thomassen 1985, Mandell et al. 1987, Bizet et 
al. 1993). In the present study, 23 out of 25 Achromobacter 
isolates were identified as A. xylosoxidans. The car-bapen-
ems were the most active antimicrobial drugs, especially 
meropenem (MIC50, 0.25 µg/ml; 88% susceptible), which 
was four-fold more potent than imipenem (MIC50, 2 µg/ml; 
84% susceptible). In contrast, amikacin had poor activity 
against these isolates. Piperacillin/tazobactam (MIC50, 
1 µg/ml; 76% susceptible) was also very active against 
Achromobacter spp. with susceptibility rate higher than 
that of trimethoprim/sulfamethoxazole (MIC50, ≤ 0.5 µg/
ml; 68% susceptible) and levofloxacin (MIC50, 2 µg/ml; 
68% susceptible). Our results are similar to those published 
by other investigators (Reverdy et al. 1984, Klinger & 
Thomassen 1985, Mandell et al. 1987, Bizet et al. 1993, 
Saiman et al. 2001).
The genus Chryseobacterium, defined in 1994 by 
Vandamme et al., comprises six species, including C. 
meningosepticum (previously Flavobacterium menin-gos-
epticum) and C. indologenes (previously F. indologenes), 
which are the most common clinical species of this genus 
(Vandamme et al. 1994).
C. meningosepticum isolates are associated with men-
ingitis in newborns or in immunocompromised patients, 
while C. indologenes is responsible mostly for nosoco-
mial infections linked to the use of intravascular devices 
(Hsueh et al. 1996, Bloch et al. 1997). Chryseobacterium 
spp. isolates are intrinsically resistant to most β-lactams, 
including carbapenems, due to production of chromo-
somally encoded metallo-β-lactamases (Bellais et al. 
2000, Kirby et al. 2004). Among the β-lactams, only pip-
eracillin and expanded-spectrum cephalosporins show in 
vitro activity against C. indologenes (Fraser & Jorgensen 
1997). Chryseobacterium spp. isolates are also resistant 
to aminoglycosides, tetracyclines, and chloramphenicol. 
All Chryseobacterium spp. isolates (12 strains) evaluated 
were resistant to imipenem and meropenem, and 75% of 
strains were also resistant to amikacin. Trimethoprim/sul-
famethoxazole (MIC50, >1µg/ml) was active against only 
36.4% of Chryseobacterium spp. strains, and gatifloxacin 
(MIC50, 0.5 µg/ml) and levofloxacin (MIC50, 0.5 µg/ml) 
were the most active compounds (75% susceptible). As 
shown in a previous study, the fluoroquinolones seem to 
be the most effective antimicrobials against Chryseobacte-
rium spp. (Kirby et al. 2004). However, the clinical use of 
the newer fluoroquinolones must be cautiously evaluated 
since therapeutic failure has been described with the use of 
ciprofloxacin (Gungor et al. 2003). Although vancomycin 
alone or in combination has been suggested as one of the 
therapeutic choices against C. meningosepticum infections 
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(Gungor et al. 2003), in vitro resistance has also been 
observed in more recent studies (Bloch et al. 1997, Fraser 
& Jorgensen 1997, Kirby et al. 2004). 
Ralstonia is a new genus that includes former members 
of Burkholderia species (B. pickettii and B. sola-nacear-
um), Alcaligenes eutrophus and CDC IVc-2 (Beringer et 
al. 2000). R. pickettii (formerly Pseudomonas picketti and 
B. pickettii) is a NF-GNB of relatively low virulence that 
can cause serious infections in im-munocompromised 
hosts (Beringer et al. 2000).  Although outbreaks have 
been reported, it is often associated with pseudobacteremia 
or asymptomatic colonization of patients. Contamination 
of water supplies, skin disinfectants, and saline solutions 
used either for patient care or for laboratory diagnosis have 
been incriminated (Roberts et al. 1990, Luk 1996, Labarca 
et al. 1999). Previous studies have shown that usually R. 
picketti isolates are susceptible to trimethoprim/sulfame-
thoxazole (Fung-Tomc et al. 1997). However, 12.5% of 
the R. picketti isolated by the Latin American medical 
centers had trimethoprim/sulfamethoxazole MICs ≥ 1 µg/
ml. The good activity of the ceftriaxone (MIC50, 1 µg/ml; 
87.5% susceptible), piperacillin/tazobactam (MIC50, 8 
µg/ml; 87.5% susceptible) and gatifloxacin (MIC50, 0.25 
µg/ml; 87.5% susceptible) observed in this study are in 
accordance with earlier studies (Fung-Tomc et al. 1997, 
Nordmann et al. 2000). 
As more patients are rendered immunossupressed by che-
motherapy, transplant or HIV infection, the increasing role of 
NF-GNB in hospital-acquired infections will be assured. Ac-
curate identification of multiply antimicrobial-resistant gram-
negative bacilli is critical to facilitate our understanding of the 
epidemiology of emerging pathogens. Furthermore, accurate 
identification and susceptibility testing of NF-GNB have 
important implications for patient treatment and guidance of 
infection control standards if patient-to-patient transmission is 
observed. In this context, surveillance programs such as the 
SENTRY Program, are very helpful by providing the most 
common susceptibility profile of these infrequent pathogens 
and, in this manner, guide the best empirical antimicrobial 
treatment of such infections. 
TABLE IV
Antimicrobial activity of selected antimicrobial agents against the main genera of the nonfermentative gram-negative bacilli 
isolated in Latin America (SENTRY Program, 1997-2002)
               MIC (µg/ml) a  
Bacterial species/antimicrobial agent MIC50 MIC90 % susc.
b % res.b
Achromobacter spp.c (25)    
Piperacillin/tazobactam     1   64   76.0     8.0
Ceftazidime     8 >16   64.0   16.0
Cefepime   16 >16   24.0   36.0
Imipenem      2     8   84.0     8.0
Meropenem         0.25     8   88.0     4.0
Ciprofloxacin     2   >2   32.0   48.0
Gatifloxacin     2   >4   60.0   12.0
Levofloxacin     2   >4   68.0   16.0
Amikacin  >32 >32   16.0   72.0
Trimethoprim/sulfamethoxazole     ≤0.5   >2   68.0   32.0    
Alcaligenes spp.d (12)    
Piperacillin/tazobactam     ≤0.5   32   83.3     8.3
Ceftazidime     4 >16   75.0   25.0
Cefepime     8 >16   58.3     8.3
Imipenem      1     2 100.0     0.0
Meropenem          0.25        0.5 100.0     0.0
Ciprofloxacin     1   >2   58.3   25.0
Gatifloxacin     1   >4   66.7   25.0
Levofloxacin     1   >4   66.7   25.0
Amikacin   16 >32   50.0   41.7
Trimethoprim/sulfamethoxazole     ≤0.5   >2   66.7   33.3
Burkholderia spp.e (83)    
Piperacillin/tazobactam     8    64   67.5    9.6
Ceftazidime     4   16   83.1    6.0
Cefepime     8 >16   51.8   30.1
Imipenem      4   >8   60.2   26.5
Meropenem     2   >8   79.5   12.0
Ciprofloxacin     1   >2   61.4   18.1
Gatifloxacin     1   >4   79.5   10.8
Levofloxacin     1     4   81.9     8.4
Amikacin >32 >32   18.1   60.2
Trimethoprim/sulfamethoxazole    ≤0.5    >1   71.1   28.9

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        MIC (µg/ml)a  
Bacterial species/antimicrobial agent MIC50 MIC90 % susc.
b % res.b
Chryseobacterium spp. f (12)    
Piperacillin/tazobactam     4 >64   58.3   25.0
Ceftazidime >16 >16   41.7   58.3
Cefepime   16 >16   41.7   41.7
Imipenem    >8   >8     0.0 100.0
Meropenem   >8   >8     0.0 100.0
Ciprofloxacin       0.5   >2   66.7   25.0
Gatifloxacin       0.5   >4    75.0   25.0
Levofloxacin       0.5     4    75.0     0.0
Amikacin >32 >32      0.0   75.0
Trimethoprim/sulfamethoxazole   >1    >1    36.4   63.6    
Ralstonia pickettii (16)    
Piperacillin/tazobactam     8    32    87.5     6.3
Ceftriaxone      1 >32    87.5   12.5
Ceftazidime >16 >16   18.8   62.5
Cefepime     2 >16   81.3   18.8
Imipenem      2     8   81.3     6.3
Meropenem     8   >8   43.8   50.0
Ciprofloxacin         0.25   >2   81.3   12.5
Gatifloxacin         0.25     4   87.5     6.3
Levofloxacin     ≤0.5     4   81.3     6.3
Amikacin    16 >32   56.3   31.3
Tetracycline   ≤4   >8   68.8   18.8
Trimethoprim/sulfamethoxazole      ≤0.5   >1   87.5   12.5    
a: minimal inhibitory concentration was determined by broth microdilution method; b: susceptibility rates calculated according to the 
criteria published by the NCCLS for testing non-Enterobacteriaceae except for trimethoprim/sulfamethoxazole. Isolates exhibiting 
MICs ≥ 1 µg/ml were considered as resistant to trimethoprim/sulfamethoxazole; c: includes Achromobacter xylosidans (22) and 
Achromobacter spp. (3); d: includes Alcaligenes faecalis (6) and Alcaligenes spp. (6); e: includes Burkholderia cepacia (80) and 
Burkholderia gladioli (3); f: includes Chryseobacterium indologenes (6) and Chryseobacterium meningosepticum (6).
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